In the two years since the Tear Film & Ocular Surface Society second Dry Eye Workshop (TFOS DEWS II) reports were published, most would agree that dry eye disease (DED) is closer to reaching household
Inflammation has been implicated in the pathogenesis of dry eye disease (DED)1,2, most notably in conditions such as Sjögren’s syndrome. However, in meibomian gland disease, considered the most
Measurement of tear film breakup time is commonly used to assess tear film stability, which is important in diagnosing and monitoring dry eye disease (DED). Although sodium fluorescein instillation is
It’s been full steam ahead for the Ocular Surface Laboratory (OSL) this year in the wake of TFOS DEWS II, ably assisted by Dr Alex Muntz, who joined the team in 2018. Research in the lab has continued
The Dunedin Multidisciplinary Health and Development Study is a large longitudinal study investigating human health, development, ageing and behaviour, based on a population-representative cohort born
Virtually all patients encounter streams of salty water coursing down their cheeks early in life and don’t realise they have more than one type of tears. More widely recognised, reflex tears serve as
Some of the most convincing evidence to date to support the effectiveness of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) has recently been established from Ally Xue’s PhD
Following the completion of their optometry honours research project on castor oil as a topical blepharitis treatment, University of Auckland now-graduated students Marna Claassen, Alice Jackson and
Since completing her work as vice-chair of TFOS DEWS II and initiating a plethora of significant research at home and in collaboration with several overseas institutions through the Ocular Surface
After many years of preparation, a dedicated dry eye clinic at the Montreal School of Optometry was inaugurated in 2012, a first within a North American Optometry school. Beginning with only half a
Eye care practitioners are well aware that medications for patients with ocular surface disease need to be proven safe through clinical trials. They probably also assume, like their patients, that
July 2019 marked the evolution and merger of ODMA and the SRC conference into O=Mega, complete with trade fair, clinical lectures, dispensing master classes and all the social stuff. The conference